Baxter submits BLA for OBI-1 in acquired hemophilia A, supplemental filing for Rixubis
This article was originally published in Scrip
Baxter International submitted a biologics license application (BLA) to the US FDA for OBI-1 (recombinant porcine factor VIII) in the treatment of acquired hemophilia A less than a year after the company acquired the product candidate from Inspiration Pharmaceuticals.
You may also be interested in...
Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.